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Background: Chemoresistance is a major factor involved in a poor response and reduced overall survival in
patients with advanced breast cancer. Although extensive studies have been carried out to understand the
mechanisms of chemoresistance, many questions remain unanswered.
Methods: In this research, we used two isogenic MCF-7 breast cancer cell lines selected for resistance to doxorubicin
(MCF-7DOX) or docetaxel (MCF-7TXT) and the wild type parental cell line (MCF-7CC) to study mechanisms underlying
acquired resistance to taxanes in MCF-7TXT cells. Cytotoxicity assay, immunoblotting, indirect immunofluorescence and
live imaging were used to study the drug resistance, the expression levels of drug transporters and various tubulin
isoforms, apoptosis, microtubule formation, and microtubule dynamics.
Results: MCF-7TXT cells were cross resistant to paclitaxel, but not to doxorubicin. MCF-7DOX cells were not cross-resistant
to taxanes. We also showed that multiple mechanisms are involved in the resistance to taxanes in MCF-7TXT cells. Firstly,
MCF-7TXT cells express higher level of ABCB1. Secondly, the microtubule dynamics of MCF-7TXT cells are weak and
insensitive to the docetaxel treatment, which may partially explain why docetaxel is less effective in inducing M-phase
arrest and apoptosis in MCF-7TXT cells in comparison with MCF-7CC cells. Moreover, MCF-7TXT cells express relatively
higher levels of β2- and β4-tubulin and relatively lower levels of β3-tubulin than both MCF-7CC and MCF-7DOX cells. The
subcellular localization of various β-tubulin isoforms in MCF-7TXT cells is also different from that in MCF-7CC and
MCF-7DOX cells.
Conclusion: Multiple mechanisms are involved in the resistance to taxanes in MCF-7TXT cells. The high expression level
of ABCB1, the specific composition and localization of β-tubulin isoforms, the weak microtubule dynamics and its
insensitivity to docetaxel may all contribute to the acquired resistance of MCF-7TXT cells to taxanes.
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Microtubule dynamicsBackground
Breast cancer is the most common type of cancer in
women and accounts for one third of all cancers in
women. The incidence of breast cancer is continuously
increasing, with more than one million reported new cases
diagnosed per year worldwide [1-3]. Among these cases,
20-30% present with metastatic or locally advanced disease,* Correspondence: zhixiang.wang@ualberta.ca
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stated.and another 30% will develop recurrent or metastatic
disease [3].
Chemotherapy is often used to treat breast cancer in
both the adjuvant and neoadjuvant settings and often in-
volves the administration of anthracyclines together with
(or followed by) taxanes. Typical taxanes used in current
treatment regimens for breast cancer include paclitaxel
(Taxol) and docetaxel (Taxotere), while typical anthracy-
clines include doxorubicin (Adriamycin) and epirubicin
(Pharmorubicin) [4,5]. Docetaxel belongs to the group of
taxanes that were first introduced into clinical use duringtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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in assembled tubulin, thereby reducing depolymerisation
[6]. Taxanes stabilise microtubules and dampens micro-
tubule dynamics to prevent the normal formation of mi-
totic spindles [6]. This leads to chronic activation of the
spindle assembly checkpoint (SAC), which in turn leads to
mitotic arrest [7]. Extended mitotic arrest eventually leads
to cell death [8]. We have recently shown that the taxanes
also strongly induce TNF alpha production, which may
also promote apoptosis through binding to its receptor
TNFR1 [9]. On the other hand, doxorubicin is an anthra-
cycline antibiotic, which intercalates with DNA. While the
mechanisms of action are not yet completely understood,
one very important component of the activity of doxoru-
bicin is its interaction with chromatin and its constitutive
components: DNA and histones. These interactions lead
to chromatin unfolding and aggregation. This chromatin
structural disruption is likely to interfere with DNA repli-
cation and transcription, which eventually leads to cell
apoptosis. It was also suggested that doxorubicin interacts
with key cellular enzymes such as topoisomerases I and II.
Topoisomerase II mediated DNA damage by doxorubicin
is followed by G1 and G2 growth arrest and induction of
apoptosis, which correlates with tumor response and pa-
tient outcomes [1,10-12].
Resistance to chemotherapy can occur prior to drug
treatment (primary or innate resistance) or develop over
time following exposure to a given chemotherapeutic
agent (acquired resistance) [13]. Chemoresistance presents
a major obstacle to therapy and leaves few effective treat-
ment options [5]. Both innate and acquired resistance to
taxanes and doxorubicin are common as more breast can-
cer patients receive these drugs [1,14]. The most esta-
blished in vitro mechanism for resistance to more than
one chemically unrelated class of agents (multidrug re-
sistance) is the overexpression of drug efflux proteins.
The best known drug efflux proteins are members of
the ATP-binding cassette (ABC) superfamily, including
P-glycoprotein [Pgp; also called multidrug resistance
protein (MDR) or ABCB1], the multidrug resistance-
associated protein 1 [MRP-1, also called ABCC1], and
the breast cancer resistance protein [BCRP, also called
ABCG2]. ABC transporter substrates include a diverse
array of compounds, many of them structurally unrelated.
These proteins protect cells and tissues by exporting
potential toxins, including anticancer agents from cells in
normal tissues and cancer cells [4]. In general, ABCB1
transports large hydrophobic compounds, whereas ABCC1
and ABCG2 transport both hydrophobic drugs and large
anionic compounds [15]. ABC proteins have been im-
plicated in both taxane and doxorubicin resistance in
breast cancers [1,3,4,14]. When 60 cell lines were tested, it
was found that the lower the ABCB1 expression level, the
greater the sensitivity to paclitaxel in the cell lines [16].However, in clinic studies the results are controversial.
One study shows that increased ABCB1 expression level is
correlated with shortened disease-free survival [17]. Some
other studies show that no correlation between ABCB ex-
pression level and response to either paclitaxel or docetaxel
treatment in breast cancer patients [18]. On the other
hand, both ABCC1 and ABCG2 mediate resistance to
doxorubicin, but not paclitaxel [5,19].
Resistance may also arise from the expression of pro-
teins underlying a specific drug’s mechanism of action.
For example, taxanes operate by binding to β-tubulin.
Taxane-resistant cancer cells may have altered expres-
sion and function of certain β-tubulin isotypes, caused
by mutations in β-tubulin, and increased microtubule
dynamics associated with altered microtubule-associated
protein (MAP) expression [3,4,14,20-23]. Altered expres-
sion of the topoisomerase IIa gene (TOP2A), which
encodes the enzyme target of the anthracyclines, may
confer anthracycline resistance [24].
Chemoresistance is a major factor involved in poor re-
sponse and reduced overall survival in patients with locally
advanced and metastatic breast cancer. Chemoresistance
is a very challenging and complex phenomenon involving
a number of complex mechanisms. Elucidating these me-
chanisms is crucial to understanding how to improve the
use of taxane and doxorubicin in cancer treatment.
Although extensive studies have been carried out to
understand chemoresistance in breast cancer both in vitro
and clinically, many questions remain unanswered. In
previous research, we established several drug-resistant
MCF-7 cell lines by exposing MCF-7 cells to increasing
concentrations of specific chemotherapy drugs [25]. Our
study showed that while drug transporters were induced
during selection for drug resistance (which reduced drug
accumulation into tumour cells), additional drug-trans-
porter-independent mechanisms must play important roles
[25]. In the current study, we used two of our preciously
created resistant cell lines, doxorubicin-resistant MCF-7
cells (MCF-7DOX) and docetaxel-resistant MCF-7 cells
(MCF-7TXT), to study the mechanisms underlying the
acquired drug resistance, with emphasis on the resistance
to taxanes in MCF-7TXT cells. We show that MCF-7TXT
cells are ten times more resistant to both docetaxel
and paclitaxel than the sensitive wild type parental cell
line (MCF-7CC). MCF-7DOX cells are eight times more
resistant to doxorubicin than MCF-7CC cells. However,
MCF-7TXT cells are not cross-resistant to doxorubicin and
MCF-7DOX cells are not cross-resistant to taxanes. We
also showed that multiple mechanisms are involved in the
resistance to taxanes in MCF-7TXT cells. Firstly, the se-
lected chemo-resistant cell lines express higher levels of
certain ABC proteins. The expression level of ABCB1 is
very high only in the MCF-7TXT cells and the expression
level of ABCC1 is very high only in the MCF-7DOX cells.
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selected chemo-resistant and the parental MCF-7 cell
lines. Moreover, MCF-7TXT cells are also more resistant to
taxane-induced mitotic spindle disruption and M phase
arrest, which leads to apoptosis. The microtubule dyna-
mics of MCF-7TXT cells are insensitive to the docetaxel
treatment, which may partially explain why docetaxel is
less effective in inducing M-phase arrest and apoptosis
in MCF-7TXT cells in comparison with MCF-7CC cells.
Finally, MCF-7TXT cells express relatively higher levels of
β-2 and β-4 tubulin and relatively lower levels of β-3
tubulin than both MCF-7CC and MCF-7DOX cells. The
subcellular localization of various β-tubulin isoforms in
MCF-7TXT cells is also different from that in MCF-7CC
and MCF-7DOX cells.
Methods
Cell culture and treatment
The cell lines that were used in this study include MCF-7
breast cancer cells selected for resistance to doxorubi-
cin (MCF-7DOX) and docetaxel (MCF-7TXT), and the
non-resitant wild type parental cell line (MCF-7CC) as
we previously described (Hembruff [25]). Detailed se-
lection process and characterization of these selected
cell lines were described previously [25]. All cells were
grown at 37°C in Dulbecco's modified Eagle's medium
containing 10% FBS supplemented with non-essential
amino acids and were maintained in a 5% CO2 atmos-
phere. MCF-7DOX cells were maintained at 95 nM doxo-
rubicin and MCF-7TXT cells were maintained at 5 nM
docetaxel.
Antibody and chemicals
Mouse monoclonal anti-ABCG2 (BXP-21), rabbit poly-
clonal anti-MDR (ABCB1) (H-241), and rabbit polyclonal
anti-MRP1 (ABCC1) (E-19) antibodies were purchased
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Rabbit anti-tubulin β1 and β3, and mouse monoclonal
anti-tubulin β2 and β4 antibodies were purchased from
Abcam (Toronto, ON). All secondary antibodies conju-
gated with FITC and TRITC were from Life Technologies
Inc (Burlington, ON). Mammalian Protein Extraction
Reagent (M-Per) was purchased from Thermo Fisher
Scientific Inc. (Rockford, IL USA). Vybrant MTT Cell Pro-
liferation Assay Kit and GFP tagged α-tubulin with the
CellLight® Reagents BacMam 2.0 were from Invitrogen
(Grand Island, NY). Unless otherwise specified, all chemi-
cals were purchased from Sigma-Aldrich.
Cytotoxicity assay
Cells were plated onto 96-well plates, 10,000 cell/well
for each MCF-7 cell line. Forty-eight hours later, the cul-
ture medium was replaced by fresh medium containing
various concentrations of Doxorubicin, paclitaxel anddocetaxel for 24 h. The percentages of viable cells were
then determined by the conversion of the water soluble
MTT (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium
bromide) to an insoluble formazan, relative to drug free
controls, using the Vybrant MTT Cell Proliferation Assay
Kit (Invitrogen, Grand Island, NY). All cytotoxicity data
shown are the means of at least three independent ex-
periments. Similar experiment were performed with drug
treatment for 72 h.
Immunoblotting
The expression levels of various proteins were examined
by immunoblotting as previously described [26]. Briefly,
protein lysates from three MCF-7 cell lines treated or not
treated with docetaxel were obtained by lysing cells with
M-PER Mammalian Protein Extraction Reagent and a
protease inhibitor cocktail. The expression of various pro-
teins including ABCB1, ABCC1, ABCG2, β1-, β2-, β3-,
and β4-tubulin was examined by immunoblotting follo-
wing SDS PAGE.
Apoptosis assay
Cell apoptosis was determined by chromatin condensa-
tion and nuclear morphology. Cells in cover slips were
treated with various concentrations of drugs for 24 h.
DNA was stained by DAPI (300 nM) for 5 min. Chro-
matin condensation and nuclear morphology were ex-
amined using a Delta Vision microscopic system. Delta
Vision SoftWoRx software was used to deconvolve the
images.
Indirect immunofluorescence
Indirect immunofluorescence was carried out as previously
described [26]. For the staining of ABC proteins, cells were
either treated or not treated with docetaxel at indicated
concentrations for 24 h. After fixation with -20°C metha-
nol, cells were incubated with antibodies against ABCB1,
ABCC1 or ABCG2, followed by FITC-conjugated secon-
dary antibodies. Nuclei were then count stained with
DAPI. For the expression and localization of α-tubulin and
various β-tubulin isoforms including β1, β2, β3, and β4,
cells were incubated with the antibodies against these
tubulins followed by incubation with TRITC-conjugated
secondary antibodies. The images were obtained using a
Delta Vision microscopic system. Delta Vision SoftWoRx
software was used to deconvolve the images.
Live imaging
Live imaging was used to study docetaxel induced
M-phase arrest and microtubule dynamics. As previously
described [26], MCF-7CC and MCF-7TXT cells were
cultured on 35 mm poly-L-lysine-coated coverslips
(Fisher) overnight. To assay docetaxel-induced M-phase
arrest, cells were incubated with DMEM containing
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stain DNA. Then, the coverslip was mounted on a sample
holder and incubated with DMEM without phenol red,
supplemented with 10% FBS with or without docetaxel.
To assay microtubule dynamics, the cells were transfected
with GFP tagged α-tubulin with the CellLight® Reagents
BacMam 2.0 (Invitrogen, Grand Island, NY) for 24 h
according to the Manufacturer’s instruction. The coverslip
was then mounted on a sample holder and incubated with
DMEM without phenol red, supplemented with 10% FBS
either with or without docetaxel of indicated concentra-
tions for 1 h.
Experiments were performed in a chamber maintained
at 37°C and 5% CO2. The fluorescence images were ac-
quired at various time intervals for indicated time using
a Delta Vision microscopic system. Delta Vision Soft-
WoRx software was used to deconvolve images and
generate movies. To calculate the extension and shor-
tening rate of the microtubules, we followed the mi-
crotubules that were either growing or shrinking. For
each datum, at least 20 microtubules from 8 cells were
measured.
Results
Cross-resistance of MCF-7CC, MCF-7DOX, and MCF-7TXT cells
to various cancer drugs
We first determined whether the selected drug resistant
cell lines show cross-resistance to different drugs. The
three cell lines used in the experiments include Doce-
taxel-resistant MCF-7 cells selected with increased doce-
taxel concentration (MCF-7TXT), Doxorubicin-resistant
MCF-7 cells selected with increased doxorubicin concen-
tration (MCF-7DOX), and the parent non-resistant MCF-7
cell line (MCF-7CC) [25]. The sensitivity of MCF-7CC,
MCF-7TXT and MCF-7DOX cells to various drugs was
determined by using a cytotoxicity assay based on the
Vybrant MTT Cell Proliferation Assay following drug
treatment for 24 h (Figure 1) or 72 h (data not shown).
The patterns were similar for both 24 and 72 h drug treat-
ment, but 72 h treatment shifted the curve downward.
Based on the dose-response curve from this cytotoxicity
assay, the IC50s for various drugs were calculated for
the above cell lines (Table 1). As shown in Table 1,
MCF-7DOX cells were nearly 8 times more resistance to
Doxorubicin than MCF-7CC cells; however, MCF-7DOX
cells showed no resistance to paclitaxel and docetaxel.
In fact MCF-7DOX cells are slightly more sensitive to
paclitaxel and docetaxel than MCF-7CC cells. Similarly,
MCF-7TXT cells were 10 times more resistant to paclitaxel
and docetaxel than MCF-7CC cell, but showed no resis-
tance to Doxorubicin. These data indicate that docetaxel-
resistant MCF-7TXT cells are cross-resistant to paclitaxel.
However, MCF-7TXT and MCF-7DOX cells show no cross-
resistance to doxorubicin and taxanes, respectively.Expression and subcellular localization of ABC proteins
The most established in vitro mechanism for resistance
to more than one chemically unrelated class of agents is
the overexpression of drug efflux proteins such as ABC
proteins. We previously examined the mRNA levels of
several ABC proteins in these MCF-7 cell lines [25].
Here we quantitatively determined the expression level
and localization of several ABC superfamily proteins in-
cluding ABCB1, ABCC1 and ABCG2 by immunoblot-
ting and immuofluorescence. These three ABC proteins
were chosen because they are most studied clinically
and are very important in breast cancer [19].
The expression levels of ABCB1, ABCC1 and ABCG2
were first examined by immunoblotting and quantified
by densitometry. As shown in Figure 2A&B, the expres-
sion level of ABCB1 was much higher in MCF-7TXT cells
than that in MCF-7CC and MCF-7DOX cells. The expres-
sion level of ABCC1 was much higher in MCF-7DOX
cells than that in MCF-7CC and MCF-7TXT cells. ABCG2
level was similar in all three cell lines, but slightly higher
in MCF-7DOX cells. These findings are consistent with
our previous data [25].
The expression level and the localization of ABCB1,
ABCC1 and ABCG2 were further examined by immu-
nofluorescence. As in Figure 2C, ABCB1, ABCC1 and
ABCG2 are all significantly localized to the plasma
membrane with weak intracellular stain, consistent with
their roles in drug efflux. Consistent with our immuno-
blotting data, MCF-7TXT cells showed much stronger
stain of ABCB1 than MCF-7CC and MCF-7DOX cells.
MCF-7DOX cells showed much stronger stain of ABCC1
than MCF-7CC and MCF-7TXT cells. The ABCG2 stain
was similar in all three cell lines. These results suggest
that different ABC proteins may confer resistance to dif-
ferent drugs.
The effects of docetaxel treatment on the expression and
subcellular localization of ABC superfamily proteins
We next examined whether treatment of these three cell
line with docetaxel changes the expression level or subcel-
lular localization of ABCB1, ABCC1 and ABCG2 by using
the same method described above. MCF-7CC, MCF-7TXT
and MCF-7DOX cells were treated with docetaxel of indi-
cated concentrations for 24 h. Western blotting showed
that the expression level of ABCB1, ABCC1 and ABCG2
was little changed following the treatment (Figure 3A).
Indirect immunofluorescence further showed that there
was no significant change in the expression level of
ABCB1, ABCC1 and ABCG2 (Figure 3B). The localization
of ABCB1, ABCC1 and ABCG2 was still exclusively at
the plasma membrane following docetaxel treatment
(Figure 3B). We observed a stronger stain in cells arrested
in M phase following docetaxel treatment. This stronger
plasma membrane stain of ABCB1, ABCC1 and ABCG2
Figure 1 Dose-response curve to drug treatment. Cytotoxicity of
paclitaxel, docetaxel and doxorubicin at various concentrations for
MCF-7CC, MCF-7TXT and MCF-7DOX cells was determined following
24 h drug treatment as described in Methods. The means of at least
three independent experiments are plotted. The error bar is the
standard error; most of them are smaller than the symbols of
the plot.
Table 1 IC50 (mM) of paclitaxel, docetaxel and
doxorubicin for MCF-7wt, MCF-7txt and MCF-7dox cells
(calculated from Figure 1)
Docetaxel Paclitaxel Doxorubicin
MCF-7wt 0.08 0.07 0.8
MCF-7txt 0.9 0.8 0.8
MCF-7dox 0.04 0.04 5
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ness of the cells in M phase.
The effects of cancer drugs on apoptosis and microtubule
formation
After examining the relationship between the acquired
drug resistance in MCF-7TXT/MCF-7DOX cells and the
expression level of ABC proteins, we next explored theinvolvement of other possible mechanisms. It is well
documented that taxanes kill cells by stabilizing their
microtubules, which eventually causes cellular apoptosis.
We, therefore, examined the effects of paclitaxel, doce-
taxel and doxorubicin on microtubule formation and cell
apoptosis in these cells.
Microtubule formation and the cell apoptosis were
examined by fluorescence microscopy (Figure 4). Micro-
tubule formation was assayed by the tubulin stain (red).
Cell apoptosis was determined by the nuclear conden-
sation revealed by DAPI stain (blue) (Figure 4A&B).
Cell apoptosis was quantitated by calculating the percen-
tage of apoptotic cells at each given drug concentration
(Figure 4C-D). Both paclitaxel and docetaxel induced
much stronger cell apoptosis in MCF-7CC and MCF-7DOX
cell than that in MCF-7TXT cells at a drug concentration
lower than 2 μM (Figure 4). At 10 nM, paclitaxel and
docetaxel began to induce apoptosis in MCF-7CC and
MCF-7DOX cells (10%), but a similar level of apoptosis in
MCF-7TXT cell only occurs when paclitaxel and docetaxel
reach a concentration of 100 nM. The maximum apop-
tosis (approximately 60%) in MCF-7CC and MCF-7DOX
cells was induced by paclitaxel and docetaxel at a concen-
tration of 500 nM. Meanwhile, a similar level of apoptosis
in MCF-7TXT cell was induced by paclitaxel and docetaxel
at a concentration of 10 μM. However, at a concentration
equal or above 2 μM, paclitaxel and docetaxel caused a
similar level of apoptosis in all three cell lines. More
interestingly, the percentage of apoptotic cells actually
decreased at drug concentrations higher than 2 μM in all
three cell lines. These results indicate that the resistance
of MCF-7TXT cells to paclitaxel/docetaxel is due to their
resistance to apoptosis induced by paclitaxel/docetaxel.
It is clear that paclitaxel/docetaxel induce cell apop-
tosis by stabilizing the microtubule spindle, arresting the
cell at M phase. We next examined whether the
resistance to paclitaxel/docetaxel-induced apoptosis in
MCF-7TXT cells is due to resistance to drug-induced
tubulin polymerization. As shown in Figure 4A&B, in
the absence of paclitaxel/docetaxel, cells go through
the cell cycle with the formation of normal tubulin
spindle in M phase (Figure 4A&B, Control). However,
at 10 nM, paclitaxel/docetaxel begins to arrest MCF-7 and
MCF-7DOX cells in M phase by interfering with the assem-
bling/disassembling microtubule spindle, which leads to
Figure 2 The expression and localization of ABC proteins.
(A) The expression of various ABC proteins including ABCB1, ABCC1
and ABCG2 in MCF-7CC, MCF-7TXT and MCF-7DOX cells was determined
by immunoblotting with specific antibodies. (B) Quantification of the
data from three independent experiments as described in panel A.
The intensity of the bands of ABC proteins was normalized against
the intensity of the actin loading. The error bar is standard error.
** indicates that the difference is statistically significant with p < 0.01.
(C) Immunofluorescence. The expression and the localization of various
ABC proteins including ABCB1, ABCC1 and ABCG2 in MCF-7CC,
MCF-7TXT and MCF-7DOX cells was determined by indirect
immunofluorescence. The green indicates the ABC proteins and
the blue is the DAPI stain for nucleus. Size bar: 10 μm.
Wang et al. BMC Cancer 2014, 14:37 Page 6 of 15
http://www.biomedcentral.com/1471-2407/14/37cell apoptosis as revealed by nuclear condensation. How-
ever, in MCF-7TXT cells, 10 nM of paclitaxel/docetaxel did
not interfere with microtubule spindle assembling/
disassembling, which was revealed by the presence
of mitotic cells with normal microtubule spindles. For
MCF-7CC and MCF-7DOX cells, the increase in concentra-
tion of paclitaxel/docetaxel from 10 nM to 500 nM caused
an increased prevalence of M phase arrest by forming
abnormal mitotic spindles. On the other hand, it also
stimulated strong microtubule formation for cells in inter-
phase as revealed by the thick microtubule fibers through-
out the cell. For the same range of paclitaxel/
docetaxel concentration, we observed few abnormal mi-
totic spindles and did not observe any significant change
in the microtubule formation in MCF-7TXT cells. With a
further increase of the concentration from 500 nM to
10 μM, more MCF-7TXT cells were arrested at M phase
with abnormal mitotic spindles and the formation of
microtubule fibres was strongly enhanced in interphase
cells. For MCF-7CC and MCF-7DOX cells, the percentages
of the cells arrested at M phase with abnormal mitotic
spindles were not changed significantly with the increase
of the drug concentration from 500 nM to 10 μM, but
microtubule formation in interphase cells was further en-
hanced. At a concentration of 50 μM, fewer cells were
arrested at M phase with abnormal mitotic spindles, but
microtubule fibres were thicker and formed circles at the
cell periphery in both MCF-7CC and MCF-7DOX cells.
Similar effects were observed in MCF-7TXT cells, but to a
lesser degree (Figure 4A&B).
Together, these results indicate that at a concentration
as high as 500 nM, paclitaxel/docetaxel do not cause
significant formation of abnormal mitotic spindles and
abnormal microtubule fibres in the taxane-resistant
MCF-7TXT cells. The resistance of MCF-7TXT cell to
paclitaxel/docetaxel is likely due to the insensitivity of
its microtubule system to the drugs.
We also examine the effects of doxorubicin on the
apoptosis and microtubule formation. As shown in
Figure 5, very few cells were arrested at the M phase with
an increased concentration of doxorubicin. Very few cells
Figure 3 The effects of docetaxel treatment on the expression
and localization of various ABC proteins in selected MCF-7 cell
lines. (A) The effects of docetaxel on the expression of ABC proteins
by immunoblotting. MCF-7CC, MCF-7TXT and MCF-7DOX cells were
treated with docetaxel at indicated concentration for 24 hours. The
cells were then lysed and expression level of ABCB1, ABCC1 and
ABCG2 in the cells was examined by immunoblotting with specific
antibodies. (B) The effects of docetaxel on the expression of ABC
proteins by indirect immunofluorescence. MCF-7CC, MCF-7TXT and
MCF-7DOX cells were seeded on coverslip and treated with docetaxel
of indicated concentrations for 24 hours. The localization and
expression of ABCB1, ABCC1 and ABCG2 in the cells were examined by
indirect immunofluorescence. The green indicates the ABC proteins
and the blue is the DAPI stain for nucleus. Size bar: 10 μm.
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at high doxorubicin concentrations. Very few cells were
left on the coverslips when the doxorubicin concentration
was above 1 μM in MCF-7CC and MCF-7TXT cells, or
when the concentration was above 5 μM in MCF-7DOX
cells. We have shown in Figure 1 that at 1 μM, more than
50% of the MCF-7CC and MCF-7TXT cell were killed by
doxorubicin, and at 5 μM, more than 50% of theMCF-7DOX cells were killed by doxorubicin. Thus, it
seemed that the dead cells detached from the coverslip
following their treatment with doxorubicin.
Live imaging of chromatin condensation induced by
docetaxel
We next employed a live imaging approach to examine
the effects of docetaxel on chromatin condensation (an
indicator for cell apoptosis). As shown in Figure 6A and
Additional file 1: Video S1, at a concentration of 20 nM,
docetaxel had no noticeable effects on the progression of
mitosis in MCF-7TXT cells. The cell cycle smoothly passed
through M phase with normal chromosome pairing and
segregation. However, for MCF-7CC cells, the same con-
centration of docetaxel disrupted the normal movement
of chromosomes at M phase and resulted in M-phase
arrest, leading to chromatin condensation (Figure 6B,
Additional file 1: Video S2A&B). For MCF-7TXT cells, a
concentration of 500 nM is needed for docetaxel to dis-
rupt chromosome movement during M phase and arrest
the cells at M phase with condensed chromatin (Figure 6C
and Additional file 1: Video S3A&B).
The effects of docetaxel on microtubule dynamics of
MCF-7TXT cells
To further determine whether the resistance of MCF-7TXT
cells to docetaxel is related to the insensitivity of its micro-
tubule polymerisation/depolymerisation to the drugs, we
examined the effects of docetaxel on microtubule dyna-
mics by live imaging (time-lapse microscopy). We transi-
ently expressed GFP-tubulin in MCF-7TXT and MCF-7CC
cells for 24 h. At the flat lamellar edge of interphase cells,
GFP-labeled microtubules are readily visible and can be
followed by time-lapse fluorescence microscopy. Micro-
tubule dynamics were measured by the extending and
shortening of the microtubules and expressed as μm/sec.
As shown in Figure 7, in the absence of docetaxel treat-
ment, the microtubules were more dynamic in MCF-7CC
cells than in MCF-7TXT cells. Both the extending rate and
the shortening rate of microtubules in MCF-7TXT cells
were significantly lower than those in MCF-7CC cells
(Figure 7A&B, Additional file 2: Figure S1, Additional file 3:
Video S4&5). However, the microtubule dynamics in
MCF-7TXT cells were much less sensitive to docetaxel than
those in MCF-7CC cells. At 100 nM of docetaxel, both the
extending rate and the shortening rate of microtubules
were slightly decreased in MCF-7CC cells, but not in
MCF-7TXT cells (Figure 7A&B, Additional file 4: Figure S2,
Additional file 3: Video S6&7). At a concentration of
0.5 μM, while both the extending rate and the shortening
rate of microtubules were greatly decreased in MCF-7CC
cells, microtubule dynamics were only slightly inhibited
in MCF-7TXT cells (Figure 7A, B&C, Additional file 3:
Video S8&9). At 10 μM docetaxel, the microtubules in
Figure 4 The effects of taxanes on the microtubule formation, M-phase arrest and cell apoptosis on the selected MCF-7 cell lines.
(A-B), MCF-7CC, MCF-7TXT and MCF-7DOX cells were seeded on coverslip and treated with docetaxel (A) and paclitaxel (B) of indicated concentrations
for 24 hours. The microtubule formation, M-phase arrest and cell apoptosis were determined by fluorescence microscopy. The red indicates the
α-tubulin and the blue is the DAPI stain for DNA. Size bar: 10 μm. (C&D) The effects of docetaxel (C) and paclitaxel (D) on the apoptosis of MCF-7CC,
MCF-7TXT and MCF-7DOX cells. The apoptotic cells were determined by chromatin condensation and nuclear morphology as revealed by DAPI stain in
A & B. For each data, 300 cells from at least three independent experiments were examined. The error bar is the standard error.
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http://www.biomedcentral.com/1471-2407/14/37both MCF-7CC and MCF-7TXT cells were almost com-
pletely stabilized with very low extending and shor-
tening rate (Figure 7A&B, Additional file 5: Figure S3,
Additional file 3: Video S10&11). These results indicate
that MCF-7TXT cells may have less vigorous intrinsic micro-
tubule dynamics than MCF-7CC cells. The microtubule dy-
namics in MCF-7TXT cells were ten times less sensitive to
docetaxel treatment. This insensitivity to docetaxel contri-
butes to the resistance of MCF-7TXT cells to docetaxel.
The expression levels of β-tubulin isoforms in MCF-7TXT,
MCF-7DOX, and MCF-7CC cells
We next examined the expression level of various β-
tubulin isoforms because it has been reported that themicrotubule dynamics may be related to the expression
level of various β-tubulin isoforms [3,4,14]. The expression
of α-tubulin and various β-tubulin isoforms including β1-,
β2-, β3- and β4-tubulin was examined in MCF-7TXT,
MCF-7DOX and MCF-7TXT cells by immunoblotting and
immunofluorescence. As shown in Figure 8A, the expres-
sion levels of α-tubulin and β1-tubulin were high and very
similar in the three MCF-7 cell lines. However, the ex-
pression levels of other β-tubulins were different. The
expression level of β3-tubulin in MCF-7TXT cells was sig-
nificantly lower than that in MCF-7CC and MCF-7DOX cells
(p < 0.01). On the other hand, the expression levels of β2-
and β4-tubulin in MCF-7TXT cells were significantly higher
than that in MCF-7CC and MCF-7DOX cells (p < 0.01).
Figure 5 The effects of doxorubicin on the microtubule
formation, M-phase arrest and cell apoptosis on the selected
MCF-7 cell lines. MCF-7CC, MCF-7TXT and MCF-7DOX cells were
seeded on coverslip and treated with doxorubicin of indicated
concentrations for 24 hours. The microtubule formation, M-phase
arrest and cell apoptosis were determined by fluorescence microscopy.
The red indicates the α-tubulin and the blue is the DAPI stain for DNA.
Size bar: 10 μm.
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α-tubulin and various β-tubulin isoforms in MCF-7CC,
MCF-7TXT and MCF-7DOX cells by indirect immunofluo-
rescence (Figure 8B). As shown in Figure 8B, α-tubulin
stain showed clear and intact microtubules in all three cell
lines. The β3- and β4-tubulins stain also showed clear and
intact microtubules in both MCF-7CC and MCF-7DOX
cells, but to a lesser extent in MCF-7TXT cells. However,
staining of the β1- and β2-tubulin did not appear like mi-
crotubules, but rather small dots filled the cytoplasm of
the cells. The pattern of these small tubulin dots is more
defined and localized discontinuously along the microtu-
bules in both MCF-7CC and MCF-7DOX cells. However,
the patterns of these small tubulin dots are messy and less
defined along the microtubule fibers in MCF-7TXT
cells. Another difference between MCF-7TXT cell andFigure 6 The effects of docetaxel on the M-phase arrest in MCF-7CC a
condensation and M-phase arrest of MCF-7CC and MCF-7TXT cells were examin
250 ng/ml Hoechst 33342 (Calbiochem) for 10 minutes to stain DNA. Then, th
images of cell mitosis were recorded every 2 minutes by live imaging. (A) MC
with 100 nM Docetaxel. (C) MCF-7TXT cells treated with 1 μM Docetaxel. TheMCF-7CC/MCF-7DOX cell is that in MCF-7TXT cells, the
β1- and β2-tubulin are localized more at the perinuclear
region of the cell while the β3- and β4-tubulin were loca-
lized more at the peripheral region of the cell.
Together, our results showed that the expression and
localization of the various β-tubulin isoforms were signifi-
cantly altered in MCF-7TXT cells. It is likely that the diffe-
rence in the expression level of various β-tubulin isoforms
and their subcellular localization between MCF-7TXT cells
and MCF-7CC/MCF-7DOX cells contributes to the dif-
ferences in their observed microtubule dynamics and re-
sistance to taxanes.
Discussion and conclusion
To better understand the mechanisms underlying ac-
quired resistance to taxanes in breast cancer, we utilized
previously established cell lines in which MCF-7 breast
cancer cells were selected for survival in increasing con-
centrations of doxorubicin (MCF-7DOX cells) or docetaxel
(MCF-7TXT cells) [25]. A cell line selected under identical
conditions in the absence of drug (MCF-7CC) was used as
a control.
We showed that MCF-7TXT cells that are resistant to do-
cetaxel are cross resistant to other drugs in the same
group such as paclitaxel, but are not resistant to doxorubi-
cin, a different type of cancer drug (Figure 1). Similarly,
we showed that MCF-7DOX cells are resistant to doxoru-
bicin, but not resistant to both docetaxel and paclitaxel.
These results demonstrate that the acquired chemoresis-
tance in this instance is specific to the selection agent and
it is not a consequence of the establishment of mecha-
nisms of multidrug resistance. Our finding is different
from a previous report showing that drug resistant MCF-7
cells lines also develops cross-resistance to structurally
unrelated cancer drugs [27]. However, in this previousnd MCF-7TXT cells. The effects of docetaxel on the chromosome
ed by live imaging. MCF-7 cells were incubated with DMEM containing
e cells were incubated with docetaxel of indicated concentration. The
F-7TXT cells treated with 100 nM Docetaxel. (B) MCF-7CC cells treated
Size bar: 10 μm.
Figure 7 The effects of docetaxel on the microtubule dynamics of MCF-7TXT an MCF-7CC cells. The Live imaging was performed as
described in Methods. Following the transfection of the cells with GFP-tagged α-tubulin for 24 hours, the cells were incubated with docetaxel of
indicated concentration for 1 hour. The images of microtubule dynamics of MCF-7CC and MCF-7TXT cells were recorded every 2 seconds by live
imaging. The extension rate (A) and shortening rate (B) of microtubules were measured from the recorded images. Each datum is the average of
20 measurements from at least 8 different cells. The error bar is the standard error. * indicates that the difference is statistically significant with p < 0.05.
** indicates that the difference is statistically significant with p < 0.01. (C) Selected images from the live imaging (Additional file 3: Video S8&9) of
microtubule dynamics of MCF-7CC and MCF-7TXT cells following treatment with 0.5 μM docetaxel for 1 hour. Arrow indicates the extending
microtubules. Arrow head indicates the shortening microtubules. Size bar, 10 μm.
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http://www.biomedcentral.com/1471-2407/14/37report, it is also shown that selected paclitaxel-resistant
MCF-7 cell is not cross-resistant to doxorubicin, which is
consistent to our data. Nevertheless, our data suggest that
the acquired resistance can be specific and chemotherapy
using combined drugs or alternative drugs may overcome
the resistance. Indeed, sequential single-agent therapy or
combination therapy have been used in breast cancer
treatment to overcome drug resistance [28].
We further showed that the selected chemoresistant cell
lines do have higher expression level of certain ABC trans-
porter proteins (Figure 2). The expression level of ABCB1
is very high only in MCF-7TXT cells and the expression
level of ABCC1 is very high only in MCF-7DOX cells. The
expression level of ABCG2 is similar in both the selected
chemoresistant and the parental MCF-7 cell lines andlikely did not play a role in the drug-resistant phenotypes
of these cell lines. These observations are consistent with
our previous findings regarding the transcription of these
ABC transporter genes in various selected MCF-7 cells
[25]. We also showed previously that MCF-7TXT cells have
lower accumulation of paclitaxel and MCF-7DOX cells
have lower accumulation of doxorubicin [25]. While all
of these three ABC proteins have been implicated in mul-
tiple drug resistance including taxanes and doxorubicin
[1,3,4,14,29], our results suggest that the specific member
of ABC transporter proteins that are induced during the
selection process may be different depending upon the se-
lection agent. Our results indicate that the resistance to
taxanes in MCF-7TXT cells is associated with high expres-
sion level of the ABCB1 protein, but not ABCC1 and
Figure 8 The expression and localization of various β-tubulin isoforms in selected MCF-7 cells. (A) The expression of α-tubulin and various
β-tubulin isoforms including β-1, β2, β3, and β-4 tubulin in MCF-7CC, MCF-7TXT and MCF-7DOX cells was determined by immunoblotting with specific
antibodies. (B) Quantification of the data from three independent experiments as described in panel A. The intensity of the bands of various tubulin
proteins was normalized against the intensity of the actin loading. The error bar is standard error. ** indicates that the difference is statistically
significant with p < 0.01. (C) Immunofluorescence. The expression and the localization of various tubulin proteins including α-, β1-, β2-, β3-, and
β4- tubulin in MCF-7CC, MCF-7TXT and MCF-7DOX cells was determined by indirect immunofluorescence. The red indicates the various tubulin proteins.
Size bar: 10 μm.
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other cell lines [19]. Although ABCB1, ABCC1 and
ABCG2 are all implicated in the resistance to doxorubicin
[19], the lack of cross-resistance to doxorubicin in MCF-
7TXT cells suggests that the ABCB1 overexpression alone
may not efficiently mediate the efflux of doxorubicin in
this selected MCF-7 cell line. Moreover, the overexpres-
sion of ABCC1, but not ABCB1 in MCF-7DOX cells sug-
gests that the resistance to doxorubicin is associated with
high expression of the ABCC1 protein and lack of overex-
pression of ABCB1 does not block the ability of cells to
acquire the resistance to doxorubicin. The lack of cross-
resistance to taxanes in MCF-7DOX cells also support the
previous finding that ABCC1 may be more efficient in
mediating the efflux of doxorubicin, but not taxane
[19,28]. Given that the expression of ABCG2 protein was
similar amongst MCF-7CC, MCF-7TXT, and MCF-7DOXcells, our data also suggest that resistance to either taxanes
or doxorubicin is unrelated to ABCG2 expression. Our
observation that treatment of the above cell lines with
docetaxel for 24 h did not alter the expression and
localization of these ABC proteins (Figure 3) also suggests
that docetaxel itself cannot induce the expression of ABC
transporter proteins.
It is also likely that the overexpression of any one of the
above ABC proteins is not sufficient to confer the resist-
ance to chemotherapy and other mechanisms are respon-
sible for the resistance. Indeed, as we showed previously,
while the drug resistance is related to the expression of
drug transporters and the drug accumulations in the cells,
drug transporter inhibitors are insufficient to fully re-
store sensitivity of MCF-7DOX cells to doxorubicin or
MCF-7TXT cells to docetaxel [25]. A series of experiments
are performed in this study to provide insight into the
Wang et al. BMC Cancer 2014, 14:37 Page 12 of 15
http://www.biomedcentral.com/1471-2407/14/37additional mechanisms underlying resistance to taxanes in
these cells.
We show in this study that the acquired resistance of
MCF-7TXT cells to taxanes as revealed in cytotoxicity assay
(Figure 1) is also associated with resistance to taxane-
induced apoptosis as revealed by quantification of chro-
mosome condensation (Figure 4). While some studies
suggest that MCF-7 cells are unable to go apoptosis due
to the deletion of caspase-3 gene and thus the lack of
caspase-3 protein, other studies indicate that MCF-7 cells
are able to go apoptosis due to the existence of caspase-3
independent apoptotic pathways [30-36]. We found in the
cytotoxicity assay that the total of surviving cells follow a
two-phase decrease with the increase of the concentration
of docetaxel and paclitaxel (Figure 1). A sharp decrease at
the low dose range (< 1 μM) and a further decrease at the
high dose rage (> 10 μM) following a plateau at the middle
dose range (1-10 μM). This observation is consistent with
our previous report [37]. We further showed in this study
that taxane treatment arrested the cells at M phase at the
dosage lower than 1 μM, which eventually leads to cell
apoptosis (Figure 4A). The first phase of decrease in cell
population (Figure 1) is coincident with the increase of
cell apoptosis induced by the treatment of docetaxel and
paclitaxel (Figure 4), which suggest that taxane-induced
apoptosis is likely responsible for the reduction of cell
population at the doses less than 1 μM. On the other
hand, treatment of the cells with doxorubicin did not ar-
rest the cells at M phase and did not induce significant
cell apoptosis (Figure 5). It has been reported that doxo-
rubicin interacts with topoisomerases I and II [10] leading
to DNA damage followed by G1 and G2 growth arrest,
which has been proposed to correlate with tumor re-
sponse and patient’s outcome [1,11]. The few apoptotic
cells induced by doxorubicin observed under a fluore-
scence microscope could be due to the detaching of the
apoptotic cells from the coverslip.
The interaction between taxanes and the microtubules
stabilises microtubules by reducing depolymerisation.
Stabilization of microtubules by taxane binding prevents
normal formation of mitotic spindles [6]. This leads to
chronic activation of the spindle assembly checkpoint
(SAC), which in turn leads to mitotic arrest [7]. Ex-
tended mitotic arrest eventually leads to cell death [8].
We studied the effects of taxanes on the formation of
microtubules and the mitotic spindles in MCF-7TXT,
MCF-7DOX and MCF-7CC cells by indirect immuno-
fluorescence (Figure 4A). We showed that the abnormal
mitotic spindles induced by taxane treatment are accom-
panied by the arrest of cells at M phase and the initiation of
cell apoptosis (nuclear condensation). While 10 - 100 nM
of docetaxel and paclitaxel induced significant mitotic
spindle disruption and M phase arrest in MCF-7CC and
MCF-7DOX cells, ten times higher concentrations ofdocetaxel and paclitaxel are needed to induce a similar
level of mitotic spindle disruption and M phase arrest in
MCF-7TXT cells. Thus, our data clearly suggests that the
acquired resistance to taxanes in MCF-7TXT cells is due to
the resistance to taxane-induced mitotic spindle disrup-
tion and M phase arrest.
We also examined microtubule dynamics in MCF-7TXT
cells (Figure 7, Additional file 2: Figure S1, Additional file 4:
Figure S2, Additional file 5: Figure S3 and Additional file 3:
Video S4-10). We showed that in the absence of docetaxel
treatment the microtubule dynamics are robust in both
MCF-7TXT and MCF-7CC cells, but the microtubule
dynamics are weaker in MCF-7TXT cells than that in
MCF-7CC cells. Moreover, microtubule dynamics are
greatly more insensitive to docetaxel in MCF-7TXT
calls than in MCF-7CC cells. For example, treatment with
0.5 μM docetaxel only slightly reduces the microtubule
dynamics in MCF-7TXT cells, but significantly reduced
both the shortening and extending rate of microtubules in
MCF-7CC cells. Our findings suggest that the resistant
MCF-7TXT cells have unique microtubule dynamics that
are likely unrelated to the overexpression of ABC trans-
porters. The insensitivity of microtubules to docetaxel
treatment in MCF-7TXT cells may be partially the reason
that docetaxel is less effective in inducing the M-phase ar-
rest and the apoptosis in MCF-7TXT cells in comparison
to MCF-7CC cells. This unique microtubule dynamics may
contribute to the resistance to docetaxel.
Although taxane-binding sites on microtubules are
only present in assembled tubulin [38], the stabilized mi-
crotubules are not able to extend without depolymeri-
sation. It is interesting to note that 0.5 μM docetaxel
induces very high level M-phase arrest at MCF-7TXT
cells (Figures 1 and 4), but does not significantly reduce
the microtubule dynamics in MCF-7TXT cells (Figure 7).
Similarly, 100 nM of docetaxel induces very high level
M-phase arrest at MCF-7CC cells (Figures 1 and 4), but
does not significantly reduce the microtubule dynamics in
MCF-7CC cells (Figure 7). The reason for this could be the
duration of the treatment. We assayed the M-phase arrest
and cell apoptosis following the treatment for 24 h, but we
assayed the microtubule dynamics only after the treatment
for 1 h. Besides, multiple mechanisms are involved in the
acquired resistance to docetaxel, microtubule dynamics is
just one of these mechanisms.
Finally, we showed that the all four β-tubulin isoforms
are expressed in the three MCF-7 cell lines. While the
relative expression levels of the four β-tubulin isoforms
are very similar between MCF-7DOX and MCF-7CC cells,
the relative expression levels of the β-tubulin isoforms are
quite different in MCF-7TXT cells (Figure 8). MCF-7TXT
cells have relatively higher β2- and β4-tubulin expression
and relatively lower β3-tubulin expression level (Figure 8).
These results suggest that the expression level of various
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of the MCF-7 cells in response to docetaxel treatment.
The expression levels of various tubulin isoforms have
been linked to the resistance to taxanes in breast cancers.
It has been reported that both β3- and β4-tubulin are
overexpressed in a MCF-7 cell line selected for resistant
to paclitaxel under increased paclitaxel concentration [21].
The overexpression of β3-tubulin induces paclitaxel resist-
ance by reducing the ability of paclitaxel to suppress
microtubule dynamics [20]. It is also reported that mRNA
levels of β2-, β3- and β4-tubulin are significantly upre-
gulated in paclitaxel- and docetaxel-resistant MCF-7 cells
[23]. The MCF-7TXT cell line used in this research is
selected for resistance to docetaxel, but showed similar re-
sistance to paclitaxel. While we also found that MCF-7TXT
cells have higher β2- and β4-tubulin expression than
MCF-7CC and MCF-7DOX cells, we actually showed that
the β3-tubulin expression level is lower. The significant
difference in the expression levels of various β-tubulin
isoforms suggest that the composition of β-tubulin in the
formation of microtubules may contribute to the micro-
tubule dynamics and its response to taxane treatment,
which could be part of the mechanisms underlying the
acquired resistance to taxanes in breast cancer cells.
We also examined the localization of these tubulin
isoforms. We showed that the localization pattern of the
various β-tubulin isoforms in MCF-7TXT cells is different
from that of MCF-7CC and MCF-7DOX cells (Figure 8B).
While we did not know how the different subcellular
distribution of these β-tubulin isoforms affects its re-
sponse to docetaxel treatment, it is possible that the
relative composition of various β-tubulin isoforms in
microtubules and their formation pattern may play a
role in determining microtubule dynamics and sensi-
tivity of microtubules to docetaxel treatment.
As shown from this study, multiple mechanisms are
likely involved in the acquired drug resistance. Besides
discussed above, many other proteins and mechanisms
may also be involved in the acquired drug resistance. It
has been shown that extracellular matrix proteins, apop-
tosis related proteins, cytokine and growth factor signa-
ling proteins, and many other proteins are overexpressed
in the selected MCF-7 cells resistant to taxanes and
other cancer drugs [29,39,40]. It is interesting to find out
in the future study whether and how these different
mechanisms regulate drug-resistance independently or
coordinately.
In conclusion, our results suggest the presence of mul-
tiple mechanisms for acquired drug resistance to taxanes.
Prolonged exposure to taxanes may result in the selection
of the breast cancer cells that overexpress certain drug
resistance proteins, such as ABCB1 in MCF-7TXT cells,
which will lower the taxane level inside the cells and
thus contribute to the resistance to taxanes. Prolongedexposure to taxanes may also result in the selection of the
breast cancer cells that have differential expression of vari-
ous β-tubulin isoforms, such as higher β-2 and β-4 and
lower β-3 tubulin in MCF-7TXT cells. In addition, the
relative composition of various β-tubulin isoforms within
the microtubules and the specific distribution of these
β-tubulin isoforms along the microtubules may determine
the dynamics of the microtubules and its sensitivity to tax-
ane treatment. For example, in MCF-7TXT cells, the dis-
tinct distribution of the β-tubulin isoforms can be related
to the weak microtubule dynamics and its insensitivity to
taxane treatment.
Additional files
Additional file 1: Video S1-S3. Live imaging of docetaxel-induced
M-phase arrest in MCF-7wt and MCF-7txt cells. MCF-7 cells were incubated
with DMEM containing 250 ng/ml Hoechst 33342 (Calbiochem) for
10 minutes to stain DNA. Then, the cells were incubated with docetaxel of
indicated concentration. The images of cell mitosis were recorded every
2 minutes by live imaging. Video S1. MCF-7txt treated with 100 nM
docetaxel. Video S2A&B. MCF-7wt cells treated with 100 nM docetaxel.
Video S3A&B, MCF-7wt cells treated with 1 μM docetaxel.
Additional file 2: Figure S1. Selected images from the live imaging
(Additional file 3: Video S4&5) of microtubule dynamics of MCF-7wt
(A) and MCF-7txt (B) cells without docetaxel treatment. Arrow indicates
the extending microtubules. Arrow head indicates the shortening
microtubules. Size bar, 10 μm.
Additional file 3: Video S4-S11. Live imaging of the micrtotubule
dynamics of MCF-7wt and MCF-7txt cells following the treatment with
docetaxel. The Live imaging was performed as described in Methods.
Following the transfection of the cells with GFP-tagged α-tubulin for
24 hours, the cells were incubated with docetaxel of indicated concentration
for 1 hour. The images of microtubule dynamics of MCF-7wt and MCF-7txt
cells were recorded every 2 seconds by live imaging. Video S4. MCF-7wt
cells without docetaxel treatment (Control). Video S5. MCF-7txt cells
without docetaxel treatment (Control). Video S6. MCF-7wt cells treated with
100 nM docetaxel for 1 hour. Video S7. MCF-7txt cells treated with 100 nM
docetaxel for 1 hour. Video S8. MCF-7wt cells treated with 0.5 μM docetaxel
for 1 hour. Video S9. MCF-7txt cells treated with 0.5 μM docetaxel for 1
hour. Video S10. MCF-7wt cells treated with 10 μM docetaxel for 1 hour.
Video S11. MCF-7txt cells treated with 10 μM docetaxel for 1 hour.
Additional file 4: Figure S2. Selected images from the live imaging
(Additional file 3: Video S6&7) of microtubule dynamics of MCF-7wt
(A) and MCF-7txt (B) cells following treatment with 100 M docetaxel for
1 hour. Arrow indicates the extending microtubules. Arrow head indicates
the shortening microtubules. Size bar, 10 μm.
Additional file 5: Figure S3. Selected images from the live imaging
(Additional file 3: Video S6&7) of microtubule dynamics of MCF-7wt
(A) and MCF-7txt (B) cells following treatment with 10 μM docetaxel for
1 hour. Arrow indicates the extending microtubules. Arrow head indicates
the shortening microtubules. Size bar, 10 μm.
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